Stay updated on M7824 and Topotecan in Relapsed SCLC Clinical Trial

Sign up to get notified when there's something new on the M7824 and Topotecan in Relapsed SCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the M7824 and Topotecan in Relapsed SCLC Clinical Trial page

  1. Check
    4 days ago
    No Change Detected
  2. Check
    11 days ago
    Change Detected
    Summary
    The page now displays Revision: v3.4.3, replacing the previous Revision: v3.4.2.
    Difference
    0.0%
    Check dated 2026-03-07T08:54:22.000Z thumbnail image
  3. Check
    19 days ago
    No Change Detected
  4. Check
    33 days ago
    Change Detected
    Summary
    - Revision metadata updated: added v3.4.2 and removed v3.4.1; no changes to the study content, eligibility criteria, or results. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-02-14T04:05:52.000Z thumbnail image
  5. Check
    40 days ago
    Change Detected
    Summary
    - Revision: v3.4.1 replaces v3.4.0 on the page. This is a minor site maintenance update with no changes to study details or user actions.
    Difference
    0.0%
    Check dated 2026-02-07T03:47:33.000Z thumbnail image
  6. Check
    54 days ago
    Change Detected
    Summary
    Added a Show glossary option and updated metadata labels (Last Update Submitted that Met QC Criteria and No FEAR Act Data) as well as revision to v3.4.0. These changes replace the previous terms (Last Update Submitted that met QC Criteria, No FEAR Act data, and v3.3.4).
    Difference
    0.1%
    Check dated 2026-01-23T21:08:11.000Z thumbnail image
  7. Check
    61 days ago
    Change Detected
    Summary
    Revision: v3.3.4 was applied, replacing the previous v3.3.3. The update appears to be a metadata/version bump with no visible changes to the study details or eligibility information.
    Difference
    0.0%
    Check dated 2026-01-17T00:32:17.000Z thumbnail image
  8. Check
    89 days ago
    Change Detected
    Summary
    Added a Locations section and Maryland as a location. Updated from revision v3.3.2 to v3.3.3, and removed the Maryland Locations entry and the HHS Vulnerability Disclosure.
    Difference
    0.1%
    Check dated 2025-12-19T13:36:32.000Z thumbnail image

Stay in the know with updates to M7824 and Topotecan in Relapsed SCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the M7824 and Topotecan in Relapsed SCLC Clinical Trial page.